Paul W. Hoelscher
Net Worth
Last updated:
What is Paul W. Hoelscher net worth?
The estimated net worth of Mr. Paul W. Hoelscher is at least $81,733,882 as of 20 Apr 2022. He has earned $62,933,882 from insider trading and has received compensation worth at least $18,800,000 in Horizon Therapeutics Public Limited Company.
What is the salary of Paul W. Hoelscher?
Mr. Paul W. Hoelscher salary is $1,880,000 per year as Executive Vice President & Chief Financial Officer in Horizon Therapeutics Public Limited Company.
How old is Paul W. Hoelscher?
Mr. Paul W. Hoelscher is 60 years old, born in 1965.
What stocks does Paul W. Hoelscher currently own?
As insider, Mr. Paul W. Hoelscher owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Horizon Therapeutics Public Limited Company (HZNP) | Executive Vice President & Chief Financial Officer | 1,049 | $0 | $0 |
What does Horizon Therapeutics Public Limited Company do?
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC.; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; and Arrowhead Pharmaceuticals, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; Lake Forest, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.
Paul W. Hoelscher insider trading
Horizon Therapeutics Public Limited Company
Mr. Paul W. Hoelscher has made 15 insider trades between 2015-2022, according to the Form 4 filled with the SEC. Most recently he sold 21,542 units of HZNP stock worth $2,480,992 on 20 Apr 2022.
The largest trade he's ever made was exercising 215,335 units of HZNP stock on 6 Apr 2022. As of 20 Apr 2022 he still owns at least 1,049 units of HZNP stock.
Horizon Therapeutics Public Limited Company key executives
Horizon Therapeutics Public Limited Company executives and other stock owners filed with the SEC:
- Dr. Jeffrey W. Sherman F.A.C.P., FACP, M.D. (70) Executive Vice President & Chief Medical Officer
- Mr. Andy Pasternak (54) Executive Vice President & Chief Strategy Officer
- Mr. Barry J. Moze (71) Executive Vice President & Chief Admin. Officer
- Mr. Paul W. Hoelscher (60) Executive Vice President & Chief Financial Officer
- Mr. Timothy P. Walbert (58) Chairman, Pres & Chief Executive Officer